Seelos Therapeutics Stock (NASDAQ:SEEL)


RevenueOwnershipFinancialsChart

Previous Close

$3.00

52W Range

$2.77 - $844.80

50D Avg

$4.45

200D Avg

$61.56

Market Cap

$1.98M

Avg Vol (3M)

$525.30K

Beta

1.85

Div Yield

-

SEEL Company Profile


Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Apr 19, 1999

Website

SEEL Performance


SEEL Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.20M--
Operating Income$-40.50M$-70.92M$-61.67M
Net Income$-37.88M$-76.14M$-67.53M
EBITDA$-40.44M$-73.76M$-61.33M
Basic EPS$-7.73$-0.72$-0.74
Diluted EPS$-7.73$-0.72$-0.74

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 17Mar 01, 18 | 7:13 PM
Q3 17Nov 05, 17 | 5:06 AM
Q2 17Aug 02, 17 | 10:27 PM

Peer Comparison


TickerCompany
SLNOSoleno Therapeutics, Inc.
ATAIAtai Life Sciences N.V.
PULMPulmatrix, Inc.
HSTOHistogen Inc.
EWTXEdgewise Therapeutics, Inc.
GHRSGH Research PLC
MNMDMind Medicine (MindMed) Inc.
CAPRCapricor Therapeutics, Inc.
DFFNCervoMed Inc.
AKTXAkari Therapeutics, Plc
ITOSiTeos Therapeutics, Inc.
TPSTTempest Therapeutics, Inc.
ENTXEntera Bio Ltd.
MOLNMolecular Partners AG
OPTOpthea Limited
ELYMEliem Therapeutics, Inc.